Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis
Gustavo C. Medeiros(University of Maryland, Baltimore), Fernando S. Goes(Johns Hopkins University), Sagar V. Parikh(University of Michigan), Mark A. Frye(Universidade Federal do Rio Grande do Sul), Julie Nanavati(Johns Hopkins University), Todd D. Gould(University of Maryland, Baltimore), Balwinder Singh(Mayo Clinic), Eric D. Achtyes(Pine Rest Christian Mental Health Services), Nuri B. Farber(Washington University in St. Louis), William L. Prueitt(Yale University), Carlos A. Zarate(National Institutes of Health), Rodrigo Machado‐Vieira(Universidade de São Paulo), Michael F. Grunebaum(Columbia University Irving Medical Center), Sudhakar Selvaraj(The University of Texas Health Science Center at Houston)
Cited by 71
Related Papers
Canadian Network for Mood and Anxiety Treatments (<scp>CANMAT</scp>) and International Society for Bipolar Disorders (<scp>ISBD</scp>) 2018 guidelines for the management of patients with bipolar disorder
|Bipolar Disorders|2018|1.8k
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
|Pharmacological Reviews|2018|1.2k
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013
|Bipolar Disorders|2012|1.2k
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder
|The Canadian Journal of Psychiatry|2016|1.1k
The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders
|American Journal of Psychiatry|2013|754